Tu SK, Fan HJ, Shi ZW, Li XL, Li M, Song K. First platelet transfusion refractoriness in a patient with acute myelocytic leukemia: A case report. World J Clin Cases 2023; 11(29): 7156-7161 [PMID: 37946754 DOI: 10.12998/wjcc.v11.i29.7156]
Corresponding Author of This Article
Kui Song, MD, Chief Doctor, Department of Hematology, The First Affiliated Hospital of Jishou University, Intersection of Shiji Avenue and Jianxin Road, Jishou 416000, Hunan Province, China. js_hematology@163.com
Research Domain of This Article
Hematology
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Tu SK, Fan HJ, Shi ZW, Li XL, Li M, Song K. First platelet transfusion refractoriness in a patient with acute myelocytic leukemia: A case report. World J Clin Cases 2023; 11(29): 7156-7161 [PMID: 37946754 DOI: 10.12998/wjcc.v11.i29.7156]
World J Clin Cases. Oct 16, 2023; 11(29): 7156-7161 Published online Oct 16, 2023. doi: 10.12998/wjcc.v11.i29.7156
First platelet transfusion refractoriness in a patient with acute myelocytic leukemia: A case report
Sheng-Ke Tu, Hong-Jie Fan, Zi-Wei Shi, Xiao-Lan Li, Min Li, Kui Song
Sheng-Ke Tu, Hong-Jie Fan, Zi-Wei Shi, Xiao-Lan Li, Kui Song, Department of Hematology, The First Affiliated Hospital of Jishou University, Jishou 416000, Hunan Province, China
Min Li, Department of Pharmacy, The First Affiliated Hospital of Jishou University, Jishou 416000, Hunan Province, China
Author contributions: Tu SK, Li M, Fan HJ, Shi ZW, Li XL and Song K conceived and designed the study; Tu SK, Li XL and Shi ZW collected and interpreted all relevant clinical and laboratory data; Tu SK, Li M, Fan HJ, Li XL, Shi ZW and Song K prepared the manuscript; Tu SK, Li M, Fan HJ, Li XL, Shi ZW and Song K confirm the authenticity of all the raw data in this study; All authors read and approved the final manuscript.
Supported byInnovation Platform and Talent Program of Hunan Province, No. 2021SK4050.
Informed consent statement: Written informed consent was obtained from the patient for publication of this case report and the accompanying images.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
CARE Checklist (2016) statement: The authors have read CARE Checklist (2016), and the manuscript was prepared and revised according to CARE Checklist (2016).
Corresponding author: Kui Song, MD, Chief Doctor, Department of Hematology, The First Affiliated Hospital of Jishou University, Intersection of Shiji Avenue and Jianxin Road, Jishou 416000, Hunan Province, China. js_hematology@163.com
Received: June 22, 2023 Peer-review started: June 22, 2023 First decision: August 16, 2023 Revised: August 28, 2023 Accepted: September 6, 2023 Article in press: September 6, 2023 Published online: October 16, 2023 Processing time: 113 Days and 4.6 Hours
Core Tip
Core Tip: We report a rare case of first platelet transfusion failure in a patient with acute myelocytic leukemia (AML) during induction chemotherapy, which may be related to the production of platelet antibodies induced by antibiotics and excessive tumor load. This also suggests that we should consider the influence of antibiotics when the rare situation of first platelet transfusion failure occurs in patients with AML. When platelet antibodies are produced, immunoglobulins can be used to block antibodies, thereby reducing platelet destruction. For patients with platelet transfusion refractoriness, both immune and non-immune factors need to be considered and combined in clinical practice along with individualized treatment to effectively solve the problem.
